An updated cost-effectiveness analysis of evolocumab suggests that while treatment with the PCSK9 inhibitor may always be somewhat costly, it remains effective in hard-to-treat patients and its reduced list price meets cost-effectiveness thresholds across a range of CV events in patients with very-high-risk atherosclerotic CVD.
Drugmaker Pfizer hid that one of its powerful anti-inflammatory drugs for rheumatoid arthritis therapy, Enbrel, reduced the risk of Alzheimer’s disease by 64%, according to a report by the Washington Post.
The U.S. Securities and Exchange Commission (SEC) is investigating a handful of healthcare companies over potentially using intermediaries to set up bribes with Chinese government and hospital officials to sell medical equipment, according to reporting by Reuters.
The U.S. Pharmacopeia (USP) has published a new chapter on the minimum standards required to prepare, compound, dispense and repackage both sterile and non-sterile radiopharmaceuticals associated with state-licensed activities.
A 2017 update to LI-RADS included an algorithm for hepatocellular carcinoma (HCC) screening and surveillance on ultrasound. While HCC remains the sixth most common cancer, the clinical performance of US LI-RADS for diagnosing the disease has yet to be studied.
Patients with end-stage renal disease (ESRD) face higher risks of in-hospital mortality and bleeding with transcatheter aortic valve replacement (TAVR) than patients who aren’t dialysis-dependent, researchers report in the Journal of the American College of Cardiology.